Axsome Therapeutics is pleased to announce a new clinical trial of an investigational oral medication, AXS-12, for the treatment of excessive day time sleepiness and cataplexy associated with narcolepsy. Participation in this study may last up to 9 weeks. All enrolled subjects will receive study-related care at no cost.
You may be eligible if you: *
Are 18-65 years old Have a diagnosis of narcolepsy with cataplexy.
*The study doctor will discuss additional requirements.
Study sites are located in the following cities: New York, NY; Cincinnati, OH; Miami, FL; Chevy Chase, MD; Austin, TX; Alameda, CA; Colombia, SC; St. Petersburg, FL.